NASDAQ
Protagonist Therapeutics, Inc. (PTGX)
♥ 574 Thanks from members
Protagonist Therapeutics (PTGX) exhibits highly polarized sentiment, driven by a blockbuster Q2 financial performance, strong partnership economics with Takeda and J&J, and an upcoming August 2026 rusfertide PDUFA date, tempered by soaring valuations and overvaluation warnings.